Advos

Kairos Pharma Ltd. to Showcase Oncology Innovations at H.C. Wainwright Global Investment Conference

July 16th, 2025 1:15 PM
By: Advos Staff Reporter

Kairos Pharma Ltd. (NYSE American: KAPA) will present its advancements in cancer therapeutics at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its potential to address drug resistance in cancer treatments.

Kairos Pharma Ltd. to Showcase Oncology Innovations at H.C. Wainwright Global Investment Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City. The company plans to host one-on-one meetings and deliver a presentation, which will also be available virtually on their website. This participation underscores Kairos Pharma's commitment to advancing innovative solutions for drug resistance and immune suppression in cancer, a significant challenge in oncology treatment today.

The company's lead candidate, ENV105, targets CD105, a protein implicated in resistance to various cancer therapies. By focusing on CD105, ENV105 aims to reverse drug resistance, thereby enhancing the efficacy of standard treatments across multiple cancer types. Currently, ENV105 is undergoing Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer, addressing critical gaps in cancer treatment options.

This conference appearance is a pivotal opportunity for Kairos Pharma to showcase its research and development efforts to investors and the broader medical community. The implications of their work are profound, offering hope for improved outcomes for patients with cancers that have become resistant to existing therapies. For more details on Kairos Pharma's presentation, visit https://ibn.fm/s0U0R.

Source Statement

This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,

blockchain registration record for the source press release.
Back To Top